| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Protein sprouty homolog 4; Spry-4; SPRY4 |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Host | |
| Immunogen | E.coli-derived human Sprouty 4/Spry-4/SPRY4 recombinant protein (Position: M1-K297). |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Target | |
| UniProt # |
Overview
Anti-Sprouty 4/Spry-4/SPRY4 Antibody Picoband® is an antibody for SPRY4 detection raised in Rabbit (Polyclonal, Rabbit IgG), with reported reactivity: Human. Commonly used in WB, IHC, Flow Cytometry, ELISA workflows.
Key elements and design rationale
- Target: SPRY4 (sprouty RTK signaling antagonist 4); UniProt: Q9C004
- Antibody format: Rabbit, Polyclonal, Rabbit IgG
- Molecular weight: 35 kDa
- Applications: WB, IHC, Flow Cytometry, ELISA
Vendor description (summary): Boster Bio Anti-Sprouty 4/Spry-4/SPRY4 Antibody Picoband® catalog # A04343-2.
Biological background
Biological context: Suppresses the insulin receptor and EGFR-transduced MAPK signaling pathway, but does not inhibit MAPK activation by a constitutively active mutant Ras. Probably impairs the formation of GTP-Ras. Inhibits Ras-independent, but not Ras-dependent, activation of RAF1.
Expression and localization notes: cellular localization: Ruffle membrane. Peripheral membrane protein. Cytoplasmic side. Cytoplasm., tissue context: Brain..
Common research applications
- Western blotting (WB): Compare SPRY4 levels across samples and conditions using appropriate loading and biological controls.
- Immunohistochemistry (IHC): Evaluate spatial distribution of SPRY4 in tissue sections, considering fixation and antigen retrieval effects.
- Flow cytometry: Quantify SPRY4-positive populations in single-cell suspensions with appropriate gating and controls.
- ELISA: Use antibody-based detection formats to assess antigen presence or binding in plate-based assays.
Notes for experimental interpretation
- Account for isoforms, post-translational modifications, and sample-specific processing that can shift apparent molecular weight or epitope accessibility.
- Use positive/negative biological controls where possible (e.g., known-expressing cells/tissues, knockdown/knockout models) and include appropriate secondary-only/isotype controls for imaging workflows.
Additional product notes (from provided fields)
- Specificity: No cross reactivity with other proteins.
- Background: Protein sprouty homolog 4 is a protein that in humans is encoded by the SPRY4 gene. It is mapped to 5q31.3. This gene encodes a member of a family of cysteine- and proline-rich proteins. The encoded protein is an inhibitor of the receptor-transduced mitogen-activated protein kinase (MAPK) signaling pathway. Activity of this protein impairs the formation of active GTP-RAS. Nucleotide variation in this gene has been associated with hypogonadotropic hypogonadism 17 with or without anosmia. Alternative splicing results in a multiple transcript variants.
- Cross reactivity: No cross-reactivity with other proteins.
- Cellular localization: Ruffle membrane. Peripheral membrane protein. Cytoplasmic side. Cytoplasm.
- Tissue details: Brain.
- Research category: Adaptive Immunity,B Cells,Hematopoietic Progenitors,Immunoglobulins,Immunology,Lymphoid,Receptors,Stem Cells
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
